Biotech Industry · global
Mankind plans €48 million investment for 70% stake in ACTx, expanding into armored CAR-T
The investment will support two therapies for lymphoma and small cell lung cancer as they move toward human trials. Designs that add functions to T cells to prolong their cancer-fighting activity must next undergo clinical testing.
Getting immune cells to recognize cancer is only the first hurdle in cell therapy; keeping them fighting in the tumor environment is the challenge that next-generation therapies are trying to overcome. Indian drugmaker Mankind Pharma announced on October 15 that it would invest in Belgium’s Armed Cell Therapeutics (ACTx), adding “armored” CAR-T to its research and development portfolio and supporting cancer programs that have yet to enter human trials.
According to Mankind’s announcement, its Dutch subsidiary has signed a definitive agreement to acquire a 70% stake in ACTx for €48 million. Financial Express, citing a stock exchange filing, reported that the consideration will be paid entirely in cash in installments; the transaction will be completed according to the agreement’s terms, with local regulatory approvals sought as needed. The announcement therefore concerns an investment agreement and should not be taken to mean that the transaction has already closed.
In a separate financing announcement, ACTx said that, including co-investment from its founding team, the round totaled more than €50 million. The funds will be used to advance two lead programs into clinical trials and expand its research and development teams in the United States and Europe. The two programs target non-Hodgkin lymphoma and small cell lung cancer, respectively. The company’s website explicitly states that both are preparing for first-in-human trials and have not yet begun enrollment. This funding supports development work ahead of clinical validation, rather than products that already have efficacy results in patients.
CAR-T uses chimeric antigen receptors to enable T cells to recognize tumor cells. “Armored” CAR-T builds on this foundation by adding functional payloads, with the aim of reducing cell exhaustion and maintaining activity in an unfavorable tumor environment. ACTx also uses a multi-antigen recognition strategy in the hope of reducing the likelihood that cancer cells will evade recognition. However, publicly available information has not disclosed the specific antigen targets or payloads of the lead programs, making it impossible to assess their advantages over other CAR-T designs on that basis.
Mankind also said that ACTx would explore approaches to generating CAR-T cells directly inside patients’ bodies in the future. This is a separate research and development direction. The announcement has not provided specific therapy candidates, trial timelines or human data, and it should not be conflated with the two lead programs set to advance.
Background
From improving receptor recognition to adjusting the sustained function of T cells, CAR-T research and development is addressing two questions simultaneously: whether the cells can find cancer cells and whether they can remain effective over time. ACTx’s latest funding gives these engineered designs an opportunity to move toward trials in patients. Their value will ultimately depend on whether subsequent studies can demonstrate safety, depth of remission and duration of response. For the small cell lung cancer program in particular, clinical data will still be needed to determine whether it can overcome barriers to activity in solid tumors.